Skip to main content
. 2020 Apr 7;26(13):1513–1524. doi: 10.3748/wjg.v26.i13.1513

Figure 1.

Figure 1

Graphical representation of overall survival in patients diagnosed with neuroendocrine tumors treated with peptide receptor radionuclide therapy. A median survival of 12.5 mo is shown (95% confidence interval: 9.8–15.2).